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The  protein  -synuclein  is considered  central  to  the pathogenesis  of  Parkinson  disease
(PD)  on  genetic  and  histopathological  grounds.  It  is  widely  expressed  in  fetal  life  and con-
tinues  to  be highly  expressed  in adult  neural  tissues,  red blood  cells  and  platelets,  while
the remainder  of adult  tissues  are  reported  to have  little  or no  expression.  Despite  cel-
lular and  molecular  evidence  for  a role  in neuronal  function  including  synaptic  vesicle
trafﬁcking,  neurotransmitter  release,  mitochondrial  function,  lipid  metabolism,  neurogen-
esis, neuroprotection,  and  neuromelanin  biosynthesis,  mice  ablated  for  the  gene  encoding
-synuclein  (Snca)  have  little  or no neurological  phenotype.  Thus,  nearly  20 years  of inten-
sive study  have  yet to  reveal  conclusively  what  the  normal  function  of  this  highly  abundant
protein  is in  the  nervous  system.  Interestingly,  -synuclein  has also  been  shown  to  have
enzymatic  activity  as  a ferrireductase  capable  of  reducing  Fe+3 to Fe+2. Given  its  abundant
expression  in  red  blood  cells,  we  set  out  to explore  the  role  of  -synuclein  in  converting
chemically-induced  Fe+3 methemoglobin  to  normal  Fe+2 hemoglobin.  Initial  in  vivo exper-
iments  with the  potent  methemoglobin  inducer,  para-aminopropiophenone  and  its  active
metabolite,  4-hydroxy  para-aminopropiophenone,  demonstrated  signiﬁcantly  greater  and
more  prolonged  methemoglobinemia  in  Snca−/−  mice  compared  to Snca+/+  mice.  In vitro
experiments  with  red blood  cells,  however,  and  in  vivo  experiments  in  genetically  engi-
neered  mouse  strains  that  differ in  their  -synuclein  expression  in  various  tissues,  including
the  nervous  system,  red  blood  cells  and  liver,  revealed  that contrary  to  the  initial  hypothesis,
a lack  of expression  of  -synuclein  in red blood  cells  did not  correlate  with  higher  levels or
more prolonged  duration  of methemoglobinemia.  Instead,  the  greater  sensitivity  to  chem-
ically  induced  methemoglobinemia  correlated  with  the  absence  of  hepatic  -synuclein
expression.  We  have  uncovered  a new  and  robust  whole-animal  phenotype  in mice  lacking
-synuclein that reﬂects  its  hitherto  unrecognized  role  in xenobiotic  detoxiﬁcation.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  underthe  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author at: Department of Medicine, University of California S
E-mail address: nussbaumr@humgen.ucsf.edu (R.L. Nussbaum).
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males had three copies of the PAC insertions. Because all
PAC transgenics were initially made in the FVB/N strain
while the Snca knock-out was  made in 129S6/SvEvTac,
Table 1
Mouse strains used.
Genotype Abbreviated nameY.-M. Kuo, R.L. Nussbaum / T
. Introduction
.1. The ˛-synuclein protein is implicated Parkinson
isease (PD)
The involvement of the -synuclein protein in Parkin-
on disease (PD) rests on three primary strands of evidence:
1) missense and copy number mutations in the SNCA gene
ncoding -synuclein cause autosomal dominant PD [30];
2) polymorphic alleles near the SNCA gene, some of which
ave functional impact on -synuclein expression, increase
usceptibility to PD [30]; and (3) aggregated -synuclein
rotein is a major constituent of Lewy bodies, the pathog-
omonic protein aggregates found in the nervous systems
f sporadic PD patients [3,28]. -Synuclein has a wide tis-
ue expression in fetal life [18] and continues to be very
ighly expressed in adult neural tissues, red blood cells
RBCs) and platelets [22,25,26], while the remainder of
dult tissues of the rodent or human are reported to have
ittle or no expression [31].
.2. Functions of ˛-synuclein and results from knock-out
ice
A bewildering array of cellular functions have been
roposed for -synuclein including synaptic vesicle traf-
cking, neurotransmitter release, mitochondrial function,
ipid metabolism, neurogenesis, neuroprotection, and
elanin biosynthesis [5–7,11,13]. Adding to the difﬁculty
f determining its normal function is that mice ablated
or the Snca gene appear to have little or no neurologi-
al phenotype [6,7,11,13]. -Synuclein has also been found
o have enzymatic activity as an NADH-dependent ferrire-
uctase capable of reducing Fe+3 to Fe+2 [5,10]. As with
he nervous system, no clear hematological phenotype has
een reported in Snca−/− mice either. Thus, nearly 20
ears of intensive study have yet to convincingly reveal -
ynuclein’s normal function in the nervous system or in
ematopoietic tissues.
.3. Hypothesis that ˛-synuclein is involved in recovery
rom chemically-induced methemoglobinemia
Genetic and biochemical data have clearly demon-
trated that the soluble isoform of cytochrome b5
eductase-3 (E.C. 1.6.2.2), which utilizes electrons trans-
erred from NADH via cytochrome b5, is the primary
nzyme responsible for methemoglobin (methgb) reduc-
ion in the red blood cell [23]. Nonetheless, given
-synuclein’s ferrireductase activity, combined with its
igh expression in red blood cells, we hypothesized that
t might also function, perhaps in an ancillary role, in
educing Fe+3 in methgb to Fe+2 and regenerating normal
emoglobin. We  therefore undertook a series of experi-
ents exploring the role of -synuclein in the recovery
rom chemically-induced methemoglobinemia. We  used
 series of genetically engineered mouse strains that
iffer in -synuclein expression in various tissues, includ-
ng the nervous system, RBCs and liver, to ask whether
he presence or absence of -synuclein in RBCs had
n effect on recovery from methemoglobinemia. Initialy Reports 2 (2015) 504–511 505
in vivo experiments with the potent methgb inducer, 4-
hydroxy para-aminopropiophenone (4-OHPAPP) and its
pro-drug, para-aminopropiophenone (PAPP) [14], demon-
strated a signiﬁcant prolongation of methemoglobinemia
in Snca−/− mice compared to Snca+/+ mice. In vitro
experiments with RBCs, however, revealed that, con-
trary to the initial hypothesis, a lack of expression of
-synuclein in RBCs did not correlate with prolongation of
methemoglobinemia. Instead, prolongation of chemically
induced methemoglobinemia correlated with the absence
of hepatic -synuclein expression. We  propose a new and
robust whole-animal phenotype in Snca−/− mice, albeit
one that is toxicological rather than neurological, that man-
ifests as a defect in the detoxiﬁcation of a xenobiotic in
mice.
2. Methods
2.1. Mouse strains
The mice used in these experiments were all previ-
ously published [6,16] and are summarized in Table 1.
Experimental strains used were (1) mice transgenic for a
P1-artiﬁcial chromosome (PAC) containing and express-
ing a wild-type human SNCA gene (PAC-Tg(SNCAWT)),
(2) two independent lines of mice transgenic for a
PAC containing and expressing an A53T mutant SNCA
gene (PAC-Tg(SNCAA53T)), and two lines expressing an
A30P mutant human SNCA gene (PAC-Tg(SNCAA30P)).
The PAC-Tg(SNCAWT) line was  bred onto the Snca−/−
background and then intercrossed; mice homozygous
for the transgene insertion and Snca knock-out allele
(PAC-Tg(SNCAWT)+/+; Snca−/−) were selected for further
study. The two  PAC-Tg(SNCAA53T) lines were each bred
onto the Snca−/− background to eliminate expression
of the endogenous murine -synuclein, intercrossed to
be homozygous for the transgene insertion, and ﬁnally
bred together to create a line of double transgenic
animals that lacked murine Snca expression and were
homozygous for both sites of the SNCAA53T PAC insertion
(dbl-PAC-Tg(SNCAA53T)+/+;Snca−/−). The PAC-Tg(SNCAA30P)
mice were similarly crossed to create double transgenic
animals with both PAC-SNCAA30P insertion sites in an
Snca−/− background (dbl-PAC-Tg(SNCAA30P)+/+;Snca−/−).
However, because one of the two PAC-SNCAA30P lines
carried its insertion on the X chromosome, only female
dbl-PAC-Tg(SNCAA30P) were homozygous for both PAC
insertions (four copies of the PAC insertions) whereas theSnca+/+ +/+
Snca−/−  −/− (Snca knock-out)
PAC-Tg(SNCAWT)+/+; Snca−/− wtPAC
PAC-dbTg(SNCAA53T)+/+; Snca−/− dtgA53T
PAC-dblTg(SNCAA30P)+/+; Snca−/− dtgA30P
oxicolog506 Y.-M. Kuo, R.L. Nussbaum / T
the PAC transgenic animals on a Snca−/− background
were in a mixed FVB/N × 129S6/SvEvTac background. We
therefore crossed wild-type FVB/N mice with wild-type or
Snca knock-out (Snca−/−) 129S6//SvEvTac mice to create
matched control cohorts of Snca+/+ or Snca−/− animals with
a mixed background similar to the PAC transgenic animals.
2.2. Reagents used
Para-aminopropiophenone (PAPP) was purchased from
City Chemical LLC (West Haven, CT 06516) and 4-hydroxyl
p-aminopropiophenone at >95% purity was provided by the
Vanderbilt Institute of Chemical Biology, Chemical Synthe-
sis Core (Vanderbilt University, Nashville, TN 37232-0412).
2.3. In vivo induction of methemoglobinemia
10 Snca+/+ and 11 Snca−/− mice received a single
intraperitoneal injection of 33 nmoles/kg of PAPP dissolved
at a concentration of 50 mg/ml  in DMSO; 5 Snca+/+ and
6 Snca−/− mice received 40 nmoles/kg of 4-OHPAPP dis-
solved at a concentration of 50 mg/ml  in DMSO. This dose
is well below the LD50 of 2.3 mmole/kg for mice [27]. Con-
trol mice were injected with the same volume of DMSO
without PAPP or 4-OHPAPP.
Blood samples were obtained by submandibular bleed-
ing of mice using a 5 mm lancet (Goldenrod, Medipoint, Inc)
into blood collection tubes prepared with K2EDTA·2H2O as
an anticoagulant (Safe-T-Fill, Ram Scientiﬁc). Blood sam-
ples were taken at 1, 2 and 4 h after treatment for methgb
measurements.
2.4. In vitro induction of methemoglobinemia
Blood was collected by submandibular bleeding into
K2EDTA·2H2O collection tubes and blood from mice of the
same genotype was pooled. RBCs were washed three times
at room temperature in phosphate buffered saline, pH 7.4,
and 328–330 Osm.
PAPP or PHAPP was dissolved in DMSO at 5 mg/ml
and then diluted and added to washed erythrocytes from
Snca+/+ and Snca−/− mice at 30% hematocrit at a ﬁnal con-
centration of 3 g/ml of drug and incubated at 37 ◦C. Blood
was treated with DMSO vehicle alone as a control.
2.5. Measurement of methemoglobinemia
The percent methgb in a blood sample was determined
by a modiﬁcation of a previously published method [24]. In
brief, 80 l of blood was added to 1.2 ml  of distilled water
and mixed by inversion to hemolyze the red blood cells
and to ensure complete oxygenation of hemoglobin. The
mixture was left at room temperature for 2–3 min, then
0.24 ml  of 0.5 M phosphate buffer pH 6.5 (0.22 M Na2HP04,
0.28 M KH2PO4) was added and the buffered hemolysate
was immediately cooled on wet ice, followed by centrifu-
gation at 1600 × g for 5 min  at 4 ◦C. The cleared, buffered
hemolysate is designated solution S (sample). A second
dilution, solution R (for reference), was made by adding
0.2 ml  of solution S to 1.0 ml  of 0.1 M phosphate buffer,
pH 6.5. 1 mg  of K3Fe(CN)6 was added by adding 5 l of ay Reports 2 (2015) 504–511
20% w/v  (200 mg/ml) solution in 0.1 M phosphate buffer,
and mixed by inversion and left to stand at least 5 min
at room temperature. 1 ml  of solution S was  added to a
cuvette (10-mm light path) and the absorbance at 630 nm
was  measured = S1. Immediately following measurement
of S1, 0.5 mg  of KCN was added by adding 5 l of a 10% w/v
solution (100 mg/ml) to the cuvette, and mixed by inver-
sion. After 2–3 min  to allow for air bubbles to rise from the
solution, the absorbance at 630 nm was read = S2. Solution
R was transferred to a cuvette as above and the absorbance
read at 630 nm = R1. Absorbance was  then re-read at A630
after adding 5 l of a 10% (100 mg/ml) w/v  solution of
KCN, mixing, and allowing it to stand for 2–3 min  = R2. Per-
cent methgb was  calculated as 100(S1 − S2)/6(R1 − R2). The
blood was  incubated at 37 ◦C and triplicate samples taken
at various time points for methgb measurements.
2.6. Statistical methods
Statistical signiﬁcance of elevations of methgb between
various mouse strains in vivo was  assessed by one-tailed
Mann–Whitney test (Prism, GraphPad Software). Extrap-
olated Y-intercept and slopes for in vitro studies were
calculated by linear regression (Prism, GraphPad Software).
2.7. Western blotting method and antibody for
˛-synuclein
Blood samples were prepared by mixing blood with
phosphate buffered saline buffer containing 0.5% NP-40
containing protease and phosphatase inhibitor tablets
(Roche) in 1:2 ratio, then centrifuged for 20 min  at 4 ◦C at
5000 rpm. An equal volume of the blood/PBS supernatant
and SDS buffer (30 mM Tris, pH 6.8, 2.5% SDS, 5% glycerol)
were mixed and vortexed. Then an equal total volume of
2X Laemmli buffer containing 10% beta-mercaptoethanol
was  added and the sample immediately loaded onto the
gel. Tissue samples were prepared as described previously
from mice that been perfused with phosphate-buffered
saline during euthanasia to ﬂush blood out of the vari-
ous tissues [16]. Proteins were subjected to SDS-PAGE (12%
Mini-PROTEAN TGXTM Gels -BIO RAD) and analyzed by
western blot. Mouse anti-Snca (BD Transduction Labora-
tories) and horseradish peroxidase goat anti-mouse IgG
(GE Healthcare) and either Clarity (BioRad) or Prime ECL
kits (for high sensitivity) were used. To further increase
sensitivity, cross-linking of -synuclein was  carried out by
exposing blots to 0.4% paraformaldehyde in PBS for 30 min
at room temperature prior to blocking [17].
3. Results
3.1. Chemical induction of methemoglobinemia in vivo
To test whether -synuclein functions in vivo as a
ferrireductase in RBCs, we  asked whether Snca−/− mice
would have elevated or more prolonged methemoglobine-
mia  following exposure to a single intraperitoneal injection
of PAPP (33 nmoles/kg in DMSO) or DMSO vehicle only.
Blood was obtained 1, 2 and 4 h after injection for methgb
measurement, expressed as a fraction of total hemoglobin
Y.-M. Kuo, R.L. Nussbaum / Toxicolog
Fig. 1. (A) Time course of methemoglobinemia following induction by
a  single i.p. injection of PAPP (33 nmoles/kg BW)  in 10 Snca+/+ and 11
Snca−/− mice. Methemoglobinemia was prolonged at 1 h in Snca−/−
versus Snca+/+ mice (***p = 0.00005, one-sided Mann–Whitney test). Five
mice of each genotype were available at 2 and 4 h. No signiﬁcant differ-
ence between Snca+/+ and 11 Snca−/− mice at 2 and 4 h. (B) Time course
of methemoglobinemia following induction by a single i.p. injection of
4-OHPAPP(44 nmoles/kg BW)  in 5 Snca+/+ and 6 Snca−/− mice. Methe-
moglobinemia was  prolonged at 1 h and 2 h in 6 Snca−/− versus 5 Snca+/+
mice (**p = 0.0022, one-sided Mann–Whitney test). (C) Time course of
methemoglobinemia following induction by a single i.p. injection of a
larger dose of 4-OHPAPP(60 nmoles/kg BW)  in 4 Snca+/+ and 4 Snca−/−
m
v
(
f
a
o
c
c
a
t
t
p
o
r
n
in which the SNCA gene is expressed differently in variousice. Methemoglobinemia was prolonged at 1, 1.5 and 2 h in Snca−/−
ersus Snca+/+ mice (*p = 0.05, one-sided Mann–Whitney test).
Fig. 1A). Wildtype (Snca+/+) mice had 2.4% methgb at 1 h
ollowing PAPP treatment, which then returned to baseline
t 2 h. This time course is similar to what was previously
bserved in wildtype rats and mice treated with sub-
utaneous or intraperitoneal PAPP respectively [2,27]. In
ontrast, mice lacking -synuclein had 17% methgb 1 h
fter PAPP injection, a signiﬁcantly greater level than in
he wildtype mice (p = 0.00005, one-tailed Mann–Whitney
est), with return nearly to baseline at 2 h and com-
lete recovery by 4 h. Mice treated with DMSO vehicle
nly showed no methemoglobinemia. These experimental
esults were replicated 8 times with similar results (data
ot shown). The return of methgb levels to normal was  noty Reports 2 (2015) 504–511 507
due to splenic sequestration or destruction of RBCs carry-
ing elevated methgb since the hematocrits of both sets of
animals were equal and normal, unchanged from baseline
(data not shown). Thus, the methgb induction did not cause
irreversible destruction of RBCs.
Since PAPP is a pro-drug that must be converted
in vivo to its active methgb-producing metabolite, 4-
OHPAPP [14], we  repeated the in vivo induction of
methgb with a single intraperitoneal injection of 4-OHPAPP
(40 nmoles/kg in DMSO). As before, DMSO served as a
vehicle-only control. 4-OHPAPP induced methgb in both
Snca+/+ and Snca−/− strains of mice (Fig. 1B). The Snca−/−
mice, however, had signiﬁcantly greater levels of methe-
moglobinemia at 1 h (32% compared to 14% in Snca+/+
mice, p = 0.0022, one-tailed Mann–Whitney test). Methe-
moglobinemia remained signiﬁcantly elevated at 14% in
Snca−/− 2 h after injection, as compared to the methgb
levels in the Snca+/+ mice, which had returned to base-
line by that time (p = 0.0022, one-tailed Mann–Whitney
test). Methgb levels returned to baseline in both geno-
types by 4 h after injection. Although there was  some
variability when an approximately 50% higher dose of 4-
OHPAPP (60 nmoles/kg) was  used, the more prolonged
methemoglobinemia in Snca−/− mice versus wildtype mice
was replicated (p = 0.05, one-tailed Mann–Whitney test)
(Fig. 1C).
3.2. Chemical induction of methemoglobinemia in vitro
We  then repeated the methgb induction experiments
in vitro. We  incubated RBCs from Snca+/+ and Snca−/− mice
with 3 g/ml PAPP, 3 g/ml 4-OHPAPP, or DMSO vehicle
alone. As expected, in vitro treatment of RBCs with the pro-
drug PAPP did not induce methgb (data not shown). RBCs
treated in vitro with 4-OHPAPP showed rapid and robust
methgb production. What was  surprising, however, was
that the percent methgb at a given concentration of 4-
OHPAPP was  similar in both mouse strains and then slowly
declined over a period of more than 6 h with a similar time
courses (Fig. 2). Linear regression analysis comparing the
slopes and extrapolated Y-intercepts were not statistically
signiﬁcantly different. There was also no signiﬁcant hemol-
ysis observed during the 6 h ours of incubation. There was,
therefore, little evidence that -synuclein in RBCs had an
appreciable effect on the induction of, or recovery from,
methgb induced by 4-OHPAPP in intact RBCs.
3.3. Sensitivity of transgenic mouse lines with differing
expression in red blood cells and other tissues to
chemically-induced methemoglobinemia
These results indicate that while expression of -
synuclein affects the response of mice to 4-OHPAPP
and PAPP treatments, the different response is not due
to -synuclein’s expression in RBCs. To investigate an
alternative possibility, that -synuclein is involved in
detoxiﬁcation of 4-OHPAPP, we used three transgenic micenon-neuronal tissues. We have previously generated and
published a series of transgenic mice made with human
P1-artiﬁcial chromosomes (PACs) containing the wildtype,
508 Y.-M. Kuo, R.L. Nussbaum / Toxicology Reports 2 (2015) 504–511
+/+ and
nd treatFig. 2. Time course of percent methemoglobin in washed RBCs from Snca
average of three measurements at a given time point for each genotype a
A53T mutant and A30P mutant versions of the human
SNCA gene, and crossed them all onto a mouse background
ablated for endogenous murine Snca (Table 1) [16]. In these
mice, therefore, the only -synuclein being made is human,
encoded by the transgenic PACs. The transgenic mice show
robust expression in the central and enteric nervous sys-
tems [16]. They do not, however, match wildtype mice in
their expression of -synuclein in non-neural tissues such
as blood, liver, kidney, lung and spleen (Fig. 3A and B).
In particular, while some of the PAC transgenic mice do
Fig. 3. (A) Western blot of -synuclein in red blood cells, liver, kidney, lung an
deﬁned various genotypes as described in Table 1. +/+ refers to Snca+/+, −/− 
dtgA30P refers to PAC-dblTg(SNCAA30P)+/+; Snca−/−. wtPAC refers to PAC-Tg(SNC
synuclein derived from western blot in Fig. 3A. The greater the number of “+” s
course of methemoglobinemia following induction by a single i.p. injection of 4-
described in Table 1. Each measurement is the average of 5 mice. At 1 h, methem
(**p  = 0.0011, one-tailed Mann–Whitney test) and showed a barely signiﬁcant dec
At  2 h, methemoglobinemia was prolonged 5–7 fold in Snca−/− and wtPAC lin
Mann–Whitney test). All lines recovered equally by 4 h. Snca−/− mice exposed to 3 g/ml 4-OHPAPP. Each point represents the
ment (4-OHPAPP versus vehicle only).
express -synuclein in RBCs and liver, others do not. These
mice, therefore, offered an opportunity to dissect the role
played by -synuclein expression in different tissues in the
persistent methgb we  observed in Snca−/− mice following
PAPP or 4-OHPAPP treatment. The fact that some of these
mice expressed A53T or A30P mutant rather than wild-
type -synuclein is not an impediment since Davies et al.
[10] found no difference in ferrireductase activity between
wildtype -synuclein and proteins with either the A53T or
A30 P mutations.
d spleen. Each lane is labeled with the name of the mouse strain with
refers to Snca−/−, dtgA53T refers to PAC-dbTg(SNCAA53T)+/+; Snca−/−,
AWT)+/+; Snca−/−. (B) Table giving approximate expression levels of -
igns, the stronger the expression. A “−” sign means no signal. (C) Time
OHPAPP(44 nmoles/kg BW)  in mouse strains with deﬁned genotypes as
oglobinemia was  elevated more than two-fold in Snca−/− versus Snca+/+
rease in A53T versus Snca+/+ (*p = 0.024, one-tailed Mann–Whitney test).
es versus Snca+/+ mice (**p = 0.0022, *p = 0.016, respectively, one-tailed
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n p-nitrosopropiophenone (PNPP). (B) Metabolism of PAPP and pathways
32], Bright and Marrs [4], Marrs and Bright [20], and Marrs et al. [21]).
Following in vivo exposure of the different PAC trans-
enic mice to 4-OHPAPP, we observed persistence of
ethgb, similar to what was seen with Snca−/− mice, in
he wtPAC line, while others, including the dtgA53T and
tgA30P, demonstrated a rapid reversal of the methgb
evels, similar to what has been seen in Snca+/+ mice
Fig. 3C). By comparing the pattern of expression (Fig. 3A
nd B) with the recovery of the different lines from 4-
HPAPP induced methemoglobinemia (Fig. 3C), it is clear
hat only -synuclein expression in liver, which is absent
n the Snca−/− and wtPAC lines, correlated with prolonged
ethemoglobinemia. Furthermore, the lack of -synuclein
xpression in red cells in the dtgA30P line, which showed
apid reversal of methemoglobinemia, and the robust -
ynuclein expression in kidney, lung and spleen in the
tPAC line, which showed prolonged methemoglobine-
ia, indicate there is no correlation between expression in
hose tissues and prolonged methemoglobinemia. We  con-
lude, therefore, that the persistence of methgb in Snca−/−
ice did not correlate with expression of -synuclein in
BCs, kidney, lung or spleen but, instead, correlated with
iver expression.
. Conclusions
.1. Para-aminopropiophenone and 4-hydroxy
ara-aminopropiophenoneThe high levels of -synuclein in red blood cells, com-
ined with its ferrireductase activity, led us to perform
 series of experiments exploring the role of -synuclein
n reversing chemically-induced methemoglobinemia,henone (PAPP), R NHOH in 4-hydroxyl p-aminopropiophenone; R NO2
d in generating methgb (adapted from Baskin and Fricke [1], Jagow et al.
despite there being extensive evidence that soluble
cytochrome b5 reductase-3 is the primary enzyme respon-
sible for methgb reduction in the red blood cell [23].
For these experiments, we used the compound PAPP and
its active metabolite 4-OHPAPP (Fig. 4A). As with other
derivatives of aniline, PAPP is converted into its hydroxy-
lamine derivative 4-OHPAPP, which then directly generates
methgb [1,15]. Whether the activation of PAPP to 4-
OHPAPP occurs in the liver [9] and/or in the lung [29]
is not known. Serum levels of 4-OHPAPP following PAPP
administration are quite low but the compound is still
able to generate far more methgb than would be predicted
by simple stoichiometry because, once inside the RBC, it
binds tightly to hemoglobin, oxidizes hemoglobin to gen-
erate methgb and is converted to p-nitrosopropiophenone
(PNPP). PNPP is then converted back to 4-OHPAPP by
NADPH generated by the pentose monophosphate path-
way, a cycle known as the Kreisprozess (Fig. 4B) [1]. Little
is known about the metabolic fate of 4-OHPAPP outside the
Kreisprozess [1,19].
4.2. Rejecting the hypothesis that ˛-synuclein
participates directly in correcting methemoglobinemia
A direct role for -synuclein in recovery from methgb
induction was initially supported by in vivo experiments in
which either the prodrug PAPP or its active metabolite 4-
OHPAPP delivered i.p. showed markedly prolonged methgb
levels in Snca−/− mice as compared to Snca+/+ mice. This
hypothesis, however, had to be discarded when in vitro
experiments with blood samples from Snca−/− and Snca+/+
mice showed no difference in the persistence of methgb
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induced by 4-OHPAPP. We  decided to take advantage of a
series of transgenic mice that either expressed or did not
express wildtype or mutant -synuclein in RBCs and other
non-neuronal tissues such as liver, kidney, lung and spleen
to examine the relationship between tissue expression
of -synuclein and recovery from 4-OHPAPP treatment
in vivo. Detecting even the low levels of expression of -
synuclein in some of these tissues is made possible by
crosslinking -synuclein on the western blot membrane
to increase antibody reactivity and using highly sensitive
Western blotting reagents. Using this technique, wildtype
Snca+/+ mice showed expression in the liver, as did some
of the transgenic animals, although below the level present
in the wildtype mice. We  found prolongation of methe-
moglobinemia following 4-OHPAPP treatment correlated
with a lack of expression of -synuclein in liver, and not
in RBC, kidney, lung or spleen. Although this was a surpris-
ing result in view of older published literature asserting
-synuclein was poorly expressed, if at all, in adult liver
[18,31], our observation of liver expression is supported by
the PaxDb database of protein abundance, which indicates
there is expression of the protein in liver, albeit at baseline
levels that are ∼1/30th to 1/40th that of brain [33]. Base-
line expression levels, however, may  be an underestimate
as it has been shown that -synuclein expression can be
strongly transcriptionally upregulated by liver X receptor
ligands [8].
4.3. Implications of these ﬁndings for Parkinson disease
research
In summary, we have shown that prolongation of
methemoglobinemia following PAPP or 4-OHPAPP treat-
ment is a novel phenotype for Snca−/− mice. The
phenotype does not reﬂect a direct effect of -synuclein
on reduction of methemoglobin since there was  no differ-
ence in vitro between RBCs with and without -synuclein in
their response to chemically induced methemoglobinemia.
Instead, the persistence of methemoglobinemia following
PAPP or 4-OHPAPP treatment in vivo correlated with the
absence of even the normally low levels of -synuclein
in the liver. The increased sensitivity of Snca−/− mice
to PAPP-induced methemoglobinemia cannot simply be
the result of increased conversion of the prodrug PAPP
to 4-OHPAPP since 4-OHPAPP itself results in an even
more striking difference in the level and duration of
methemoglobinemia in Snca−/− mice than does PAPP. We
believe the methemoglobinemia induced by 4-OHPAPP
simply serves as a biomarker for -synuclein’s role in
the metabolism of 4-OHPAPP and, by extension, poten-
tially other xenobiotic toxicants as well. Such a role adds
a new dimension to the longstanding debate over the
pathogenesis of PD, i.e. whether the disease is caused by
environmental exposure to toxicants [12] or by a genetic
susceptibility conferred by, among other genetic factors,
increased expression or mutation of -synuclein [30].
Instead, we propose that a direct interaction between -
synuclein and the environmental toxicants it participates
in detoxifying could cause damage to this and other pro-
teins, leading to aggregation and the initiation of a process
that ultimately leads to PD.
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